Claudia Aura

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +14

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Yasir H. Ibrahim, Celina García-García, Violeta Serra et al. · Cancer Discovery · 2012 · 622 citations · Full text

Medicine, Cancer Biology, Oncology +17

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

Roberto Salgado, Carsten Denkert, Christine Campbell et al. · JAMA Oncology · 2015 · 606 citations · Full text

Medicine, Immunology, Oncology +17

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

Pieter J.A. Eichhorn, Laura Rodón, Alba Gonzàlez-Juncà et al. · Nature Medicine · 2012 · 404 citations

Life Sciences, Molecular Biology, Oncology +12

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Leticia De Mattos‐Arruda, Britta Weigelt, Javier Cortés et al. · Annals of Oncology · 2014 · 378 citations · Full text

Medicine, Genetics, Oncology +16